Clearing the Way in Atopic Dermatitis

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

CME/MEDICAL COMMUNICATIONS INQUIRIES info@integritasgrp.com integritasgrp.com

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

3

FACULTY

Jacob P. Thyssen, MD, PhD, DmSci Professor Department of Dermatology and Venereology Bispebjerg Hospital University of Copenhagen Copenhagen, Denmark

TARGET AUDIENCE The educational design of this activity addresses the needs of pediatric dermatologists, dermatologists, and allergists involved in the ongoing management of pediatric patients with moderate-to-severe atopic dermatitis.

PROGRAM OVERVIEW Interactive Professor™ sessions are designed to educate European pediatric dermatologists, dermatologists, and allergists/immunologists involved in the ongoing management of pediatric patients with moderate-to-severe atopic dermatitis. Sessions will start approximately every 30 minutes and run continuously during designated breaks throughout the conference. Please join us for an informative and engaging session.

EDUCATIONAL OBJECTIVES After completing this activity, the participant should be better able to: • Evaluate pediatric patients with atopic dermatitis for disease severity, biopsychosocial burdens, comorbidities, and treatment responses • Discuss the clinical profiles and latest trial evidence for current and emerging targeted therapies in pediatric patients with moderate-to-severe atopic dermatitis • Construct treatment regimens for moderate-to-severe atopic dermatitis based on disease severity, comorbidities, and shared decision making with pediatric patients and their caregivers

For additional CME activities log on to

4

PHYSICIAN ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION Global Education Group designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EACCME The UEMS-EACCME® and the AMA have recognized each other’s CME credits since 2000. In 2002 the UEMS-EACCME® and the AMA signed an agreement of mutual recognition of CME credits between Europe and the USA whereby European physicians attending an event in the USA have their credits recognized in Europe and American physicians attending an event in Europe have their credits recognized in the USA. An application for EACCME credit has been submitted.

ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA Activities held outside of Canada developed by a university, academy, specialty society, or other physician organization can be recorded as accredited group learning activities under Section 1 of the Royal College of Physician and Surgeons of Canada’s Maintenance of Certification (MOC) Program.

JAPAN ACCREDITATION COUNCIL FOR MEDICAL EDUCATION CREDIT Activities certified by ACCME-accredited organizations may also allow Japanese learners to meet the criteria for Japan Accreditation Council for Medical Education credit.

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

5

INSTRUCTIONS TO RECEIVE CREDIT In order to receive credit for this activity, the participant must attend the session, complete the posttest, and complete the program evaluation.

DISCLOSURES OF CONFLICTS OF INTEREST Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies: Jacob P. Thyssen, MD, PhD Consulting Fee: AbbVie, Almirall, Arena Pharmaceuticals, Colo-plast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; Contracted Research: Pfizer, Regeneron, Sanofi-Genzyme; Speaker Honoraria: AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme The planners and managers have the following relevant financial relationships with ineligible companies: Lindsay Borvansky Andrea Funk Liddy Knight Ashley Cann Stacey Ullman Rose O’Connor, PhD, CHCP

Nothing to disclose Nothing to disclose Nothing to disclose Nothing to disclose Nothing to disclose Nothing to disclose

For additional CME activities log on to

6

DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

GLOBAL CONTACT INFORMATION For information about the accreditation of this program, please contact Global at 1-303-395-1782 or cme@globaleducationgroup.com.

FEE INFORMATION& REFUND/ CANCELLATION POLICY There is no fee for this educational activity.

INTEGRITAS COMMUNICATIONS CONTACT INFORMATION For questions about this activity, please contact Integritas Communications at info@exchangecme.com.

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

For additional CME activities log on to

7

8

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

For additional CME activities log on to

9

10

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

For additional CME activities log on to

11

12

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

For additional CME activities log on to

13

14

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

For additional CME activities log on to

15

16

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

For additional CME activities log on to

17

18

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

For additional CME activities log on to

19

20

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

21

GUIDELINES ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744. » https://onlinelibrary.wiley.com/doi/10.1111/jdv.16892

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. » https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.14891

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. » https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.14888

PATIENT RESOURCES International Eczema Council Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care. » https://www.eczemacouncil.org/

CLINICAL ASSESSMENT TOOLS Children’s Dermatology Life Quality Index (CDLQI) The CDLQI is 10-question patient-reported assessment tool designed to measure impact of any skin disease on the lives of children aged 4-16 years.

Lewis-Jones MS, Finlay AY. Br J Dermatol. 1995;132(6):942-949. » https://www.cardiff.ac.uk/medicine/resources/quality-of-life-questionnaires/childrensdermatology-life-quality-index

Patient-Oriented Eczema Measure (POEM) The POEM is a patient-oriented, self-assessment measurement tool for monitoring aspects of atopic dermatitis in routine clinical practice or in the clinical trial setting.

Charman CR, et al. Arch Dermatol. 2004;140(12):1513-1519. » https://www.nottingham.ac.uk/research/groups/cebd/resources/poem.aspx

For additional CME activities log on to

22

SUGGESTED READING Atopic Dermatitis Overview and Pathogenesis Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.

Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971. » https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840507/?report=reader

Pathogenesis of atopic dermatitis.

Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574. » https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.12495

Patient Burden and Comorbidities The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis.

Chamlin SL, et at. Arch Pediatr Adolesc Med. 2005;159(8):745-750. » https://jamanetwork.com/journals/jamapediatrics/fullarticle/486092

Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study.

Kern C, et al. JAMA Dermatol. 2021;157(10):1200-1208. » https://jamanetwork.com/journals/jamadermatology/article-abstract/2783857

‘His first word was “cream.” The burden of treatment in paediatric atopic dermatitis—a mixed methods study.

O’Connor C, et al. Dermatol Ther. 2022;35(3):e15273. » https://www.researchgate.net/publication/357110860_%27His_first_word_was_cream%27_ The_burden_of_treatment_in_paediatric_atopic_dermatitis_-_a_mixed_methods_study

Association between atopic dermatitis and suicidality: a systematic review and meta-analysis.

Sandhu JK, et al. JAMA Dermatol. 2019;155(2):178-187. » https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439544/

Increasing severity of early-onset atopic dermatitis, but not late-onset, associates with development of aeroallergen sensitization and allergic rhinitis in childhood.

Schoos AMM, et al. Allergy. 2022;77(4):1254-1262. » https://onlinelibrary.wiley.com/doi/10.1111/all.15108

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

23

Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study.

Silverberg JI, et al. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. » https://pubmed.ncbi.nlm.nih.gov/33421555/

Comorbidities and the impact of atopic dermatitis.

Silverberg JI. Ann Allergy Asthma Immunol. 2019;123(2)144-151. » https://pubmed.ncbi.nlm.nih.gov/31034875/

Management of Atopic Dermatitis Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303. » https://www.ncbi.nlm.nih.gov/pubmed/28478972

Efficacy and safety of upadacitinib vs dupilumab in adults with moderateto-severe atopic dermatitis: a randomized clinical trial.

Blauvelt A, et al. JAMA Dermatol. 2021;157(9):1047-1055. » https://jamanetwork.com/journals/jamadermatology/fullarticle/2782803

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.

Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775. » https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901393/

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomized controlled phase 3 trials.

Guttman-Yassky E, et al. Lancet. 2021;397(10290):2151-2168. » https://pubmed.ncbi.nlm.nih.gov/34023008/

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial.

Paller AS, et al. J Am Acad Dermatol. 2020;83(5):1282-1293. » https://pubmed.ncbi.nlm.nih.gov/32574587/

For additional CME activities log on to

24

Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial.

Silverberg JI, et al. JAMA Dermatol. 2020;156(8):863-873. » https://pubmed.ncbi.nlm.nih.gov/32492087/

Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial.

Simpson EL, et al. JAMA Dermatol. 2020;156(1):44-56. » https://jamanetwork.com/journals/jamadermatology/fullarticle/2753673

CLEARING THE WAY IN ATOPIC DERMATITIS A Case-Based Update on Pediatric Patients

NOTES

For additional CME activities log on to

25

26

NOTES

© 2022 Global Education Group and Integritas Communications. All rights reserved.

No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.